Hepatocellular Carcinoma: Can Circulating Tumor Cells and Radiogenomics Deliver Personalized Care?

Richard L. Hesketh, Andrew X. Zhu, Rahmi Oklu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The 'omics revolution is facilitating a personalized approach to improving outcome by refining diagnosis, staging, treatment, and monitoring of hepatocellular carcinoma. Furthermore, the promise of being able to target a range of specific tumor drivers at a molecular level offers exciting new therapy prospects for a disease that is notoriously difficult to treat. We provide a unique perspective combining our understanding of the molecular mechanisms of hepatocellular carcinoma development with the potential of circulating tumor cells and radiogenomics to change the drivers of decision-making used in current practice. ©

Original languageEnglish (US)
Pages (from-to)431-436
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume38
Issue number4
DOIs
StatePublished - Aug 6 2015
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Hepatocellular Carcinoma
Decision Making
Neoplasms
Therapeutics

Keywords

  • circulating tumor cells
  • hepatocellular carcinoma
  • radiogenomics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Hepatocellular Carcinoma : Can Circulating Tumor Cells and Radiogenomics Deliver Personalized Care? / Hesketh, Richard L.; Zhu, Andrew X.; Oklu, Rahmi.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 38, No. 4, 06.08.2015, p. 431-436.

Research output: Contribution to journalArticle

@article{12cbc15b2ea947b0bec8c0d3513c68fa,
title = "Hepatocellular Carcinoma: Can Circulating Tumor Cells and Radiogenomics Deliver Personalized Care?",
abstract = "The 'omics revolution is facilitating a personalized approach to improving outcome by refining diagnosis, staging, treatment, and monitoring of hepatocellular carcinoma. Furthermore, the promise of being able to target a range of specific tumor drivers at a molecular level offers exciting new therapy prospects for a disease that is notoriously difficult to treat. We provide a unique perspective combining our understanding of the molecular mechanisms of hepatocellular carcinoma development with the potential of circulating tumor cells and radiogenomics to change the drivers of decision-making used in current practice. {\circledC}",
keywords = "circulating tumor cells, hepatocellular carcinoma, radiogenomics",
author = "Hesketh, {Richard L.} and Zhu, {Andrew X.} and Rahmi Oklu",
year = "2015",
month = "8",
day = "6",
doi = "10.1097/COC.0000000000000123",
language = "English (US)",
volume = "38",
pages = "431--436",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Hepatocellular Carcinoma

T2 - Can Circulating Tumor Cells and Radiogenomics Deliver Personalized Care?

AU - Hesketh, Richard L.

AU - Zhu, Andrew X.

AU - Oklu, Rahmi

PY - 2015/8/6

Y1 - 2015/8/6

N2 - The 'omics revolution is facilitating a personalized approach to improving outcome by refining diagnosis, staging, treatment, and monitoring of hepatocellular carcinoma. Furthermore, the promise of being able to target a range of specific tumor drivers at a molecular level offers exciting new therapy prospects for a disease that is notoriously difficult to treat. We provide a unique perspective combining our understanding of the molecular mechanisms of hepatocellular carcinoma development with the potential of circulating tumor cells and radiogenomics to change the drivers of decision-making used in current practice. ©

AB - The 'omics revolution is facilitating a personalized approach to improving outcome by refining diagnosis, staging, treatment, and monitoring of hepatocellular carcinoma. Furthermore, the promise of being able to target a range of specific tumor drivers at a molecular level offers exciting new therapy prospects for a disease that is notoriously difficult to treat. We provide a unique perspective combining our understanding of the molecular mechanisms of hepatocellular carcinoma development with the potential of circulating tumor cells and radiogenomics to change the drivers of decision-making used in current practice. ©

KW - circulating tumor cells

KW - hepatocellular carcinoma

KW - radiogenomics

UR - http://www.scopus.com/inward/record.url?scp=84938749403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938749403&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000123

DO - 10.1097/COC.0000000000000123

M3 - Article

C2 - 25238287

AN - SCOPUS:84938749403

VL - 38

SP - 431

EP - 436

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 4

ER -